J Korean Med Sci.  2012 Sep;27(9):1079-1084. 10.3346/jkms.2012.27.9.1079.

Elevated Insulin and Insulin Resistance Are Associated with the Advanced Pathological Stage of Prostate Cancer in Korean Population

• Yun SJ
• Min BD
• Kang HW
• Shin KS
• Kim TH
• Kim WT
• Lee SC
• Kim WJ

• KMID: 1782143
• DOI: http://doi.org/10.3346/jkms.2012.27.9.1079

Abstract

The study was designed to investigate the effect of serum glucose, insulin and insulin resistance on the risk of prostate cancer (CaP) and on the clinicopathological characteristics in Korean men. Subjects were retrospectively recruited from 166 CaP patients underwent radical prostatectomy and 166 age-matched benign prostatic hyperplasia (BPH) patients. The serum was taken on the morning of the day of operation and insulin resistance was assessed by homeostasis model assessment insulin resistance index (HOMA-IR). Men in highest tertile of insulin was associated with 55% reduced odds of CaP than those with the lowest tertile (OR = 0.45, 95% CI = 0.23-0.89, P = 0.022). The patients in highest tertile of insulin had a more than 5.6 fold risk of locally advanced stage than those in the lowest tertile (OR = 5.62, 95% CI = 1.88-16.83, P = 0.002). Moreover, the patients in the highest tertile HOMA-IR group was associated with an increased risk of locally advanced stage than the lowest tertile group (OR = 3.10, 95% CI = 1.07-8.99, P = 0.037). These results suggest that elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean patients.

Keyword

Glucose; Insulin; Insulin Resistance; HOMA-IR; Prostatic Neoplasms

MeSH Terms

Aged
Asian Continental Ancestry Group
Blood Glucose/analysis
Humans
Insulin/*blood
*Insulin Resistance
Male
Middle Aged
Neoplasm Grading
Odds Ratio
Prostate-Specific Antigen/blood
Prostatectomy
Prostatic Neoplasms/etiology/*pathology
Republic of Korea
Retrospective Studies
Risk Factors
Blood Glucose
Insulin
Prostate-Specific Antigen

Reference

1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol. 2005. 16:481–488.

2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008. 58:71–96.

3. Damber JE, Aus G. Prostate cancer. Lancet. 2008. 371:1710–1721.

4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.

5. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev. 2002. 3:303–308.

6. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol. 2005. 23:4742–4754.

7. Jung KW, Park S, Kong HJ, Won YJ, Boo YK, Shin HR, Park EC, Lee JS. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010. 25:1113–1121.

8. Mydlo JH, Tieng NL, Volpe MA, Chaiken R, Kral JG. A pilot study analyzing PSA, serum testosterone, lipid profile, body mass index and race in a small sample of patients with and without carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2001. 4:101–105.

9. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol. 2000. 151:541–549.

10. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006. 17:989–1003.

11. Cho IC, Kwon WA, Kim JE, Joung JY, Seo HK, Chung J, Park WS, Lee KH. Prostate volume has prognostic value only in pathologic T2 radical prostatectomy specimens. J Korean Med Sci. 2011. 26:807–813.

12. Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, Choi YH, Kim IY, Kim WJ. Prostate size correlates with fasting blood glucose in non-diabetic benign prostatic hyperplasia patients with normal testosterone levels. J Korean Med Sci. 2011. 26:1214–1218.

13. Argiles JM, Lopez-Soriano FJ. Insulin and cancer (Review). Int J Oncol. 2001. 18:683–687.

14. Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology. 2001. 58:723–728.

15. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer Prostatic Dis. 2009. 12:259–263.

16. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006. 15:2056–2062.

17. Li Q, Kuriyama S, Kakizaki M, Yan H, Sone T, Nagai M, Sugawara Y, Ohmori-Matsuda K, Hozawa A, Nishino Y, et al. History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study. Cancer Causes Control. 2010. 21:1025–1032.

18. Harish K, Dharmalingam M, Himanshu M. Study Protocol: insulin and its role in cancer. BMC Endocr Disord. 2007. 7:10.

19. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst. 2007. 99:1793–1800.

20. Buschemeyer WC 3rd, Freedland SJ. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol. 2007. 52:331–343.

21. Hsing AW, Gao YT, Chua S Jr, Deng J, Stanczyk FZ. Insulin resistance and prostate cancer risk. J Natl Cancer Inst. 2003. 95:67–71.

22. Albanes D, Weinstein SJ, Wright ME, Mannisto S, Limburg PJ, Snyder K, Virtamo J. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst. 2009. 101:1272–1279.

23. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, Hallmans G, Kaaks R, Stattin P. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer. 2007. 120:2678–2686.

24. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Br J Cancer. 2002. 87:726–728.